Projects In Sub-Saharan Africa Propelling Drug Approval Procedures

 
• By Ian Schofield
  
Generate a summary of this article
Listen to this article
Beta

Sub-Saharan Africa has been firmly in the regulatory spotlight over the past year or so, with east and west Africa making progress on projects to speed up drug regulatory procedures through greater cooperation and information sharing at the regional level.

Lightbulbs
Scrip analyzes information sharing projects being trialed under African Medicines Regulatory Harmonization initiative • Source: Shutterstock

The projects are part of the African Medicines Regulatory Harmonization (AMRH) initiative, which was set up in 2009 to establish and bolster regulatory standards across sub-Saharan Africa with the goal of improving patient access to safe, high-quality medicines. The initiative is gaining momentum, with the setting up of regional regulatory agencies or even a pan-African body being mentioned as part of a longer-term vision.

Here Scrip looks at some of the projects that are under way or in development.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Archive

Optimizing Drug Pipelines With Biophysical Methods

Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal

 
• By Andrew McConaghie

GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains